111 related articles for article (PubMed ID: 27648713)
1. Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.
Grzankowski KS; Szender JB; Spring-Robinson CL; Lele SB; Odunsi KO; Frederick PJ
Int J Gynecol Cancer; 2016 Oct; 26(8):1440-7. PubMed ID: 27648713
[TBL] [Abstract][Full Text] [Related]
2. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
3. Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study.
Cortesi L; De Matteis E; Rashid I; Cirilli C; Proietto M; Rivasi F; Federico M
Int J Gynecol Cancer; 2009 Nov; 19(8):1358-63. PubMed ID: 20009890
[TBL] [Abstract][Full Text] [Related]
4. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
Matsuyama Y; Tominaga T; Nomura Y; Koyama H; Kimura M; Sano M; Miura S; Takashima S; Mitsuyama S; Ueo H; Ohashi Y
Ann Oncol; 2000 Dec; 11(12):1537-43. PubMed ID: 11205460
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
6. Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study.
Ursic Vrscaj M; Kovacic J; Bebar S; Djurisic A; Fras PA; Robic V
Eur J Obstet Gynecol Reprod Biol; 2001 Mar; 95(1):105-10. PubMed ID: 11267730
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunohistochemical features of primary breast cancer and metachronous ovarian and endometrial tumors.
Kryzhanivska AE; Dyakiv IB; Kyshakevych I
Exp Oncol; 2018 Jun; 40(2):124-127. PubMed ID: 29949531
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.
Olawaiye A; Caesar L; Walsh D; Lyman M; Yeh J; Rodabaugh K; Marchetti D; Lele S; Odunsi K
Gynecol Oncol; 2004 Sep; 94(3):796-802. PubMed ID: 15350375
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
14. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
15. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
16. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
17. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
[TBL] [Abstract][Full Text] [Related]
18. Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand.
Tangjitgamol S; Khunnarong J; Srijaipracharoen S
J Gynecol Oncol; 2015 Oct; 26(4):293-302. PubMed ID: 26197770
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.
Rosell J; Nordenskjöld B; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström PO; Wallgren A; Stål O; Carstensen J
Acta Oncol; 2017 Apr; 56(4):614-617. PubMed ID: 28080180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
